VYNE Therapeutics Reports the US FDA’s Acceptance of IND for VYN202 to Treat Autoimmune Diseases
Shots:
- Following the IND clearance, company plans to initiate P-Ia trial evaluating safety, tolerability, PK & PD in healthy volunteers (n=64 in 5 SAD & 3 MAD cohorts) in Q2’24, whereas topline data is anticipated by H2’24
- Upon successful completion of P-Ia part of study, the company will initiate P-Ib part in moderate-to-severe plaque Pso patients & adult-onset RA with topline data in H2’25
- VYN202 (BD2-selective BET inhibitor) attained consistent reduction in pro-inflammatory and disease-related biomarkers with improvements in disease severity in preclinical studies
Ref: VYNE Therapeutics | Image: VYNE Therapeutics
Related News:- VYNE Reports Results of FMX114 in P-Ib Portion of a P-Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
